SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals’s consolidated net profit clocks in growth of 23% in Q1

26 Jul 2011 Evaluate

Glenmark Pharmaceuticals has reported results for the quarter ended June 30, 2011.

The company‘s net profit has registered growth of 19.20% at Rs 72.46 crore for the quarter as compared to Rs 60.79 crore for the corresponding quarter of the previous year. Its total income has increased by 19.14% at Rs 330.78 crore for the Q1FY12 from Rs 277.62 crore for the Q1FY11.

On consolidated basis, the group’s net profit for the quarter ended June 30, 2011 has clocked in 23.20% growth at Rs 210.11 crore as compared to Rs 170.54 crore for the June quarter of the previous fiscal. Its total income has increased by 26.77% to Rs 880.80 crore for the quarter from Rs 694.81 crore for the June quarter of FY11.

Glenmark Pharma Share Price

2364.35 -6.70 (-0.28%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×